Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tg Therapeutics (TGTX) Net Income towards Common Stockholders (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Net Income towards Common Stockholders data on record, last reported at -$84.7 million in Q4 2025.

  • For Q4 2025, Net Income towards Common Stockholders fell 2607.86% year-over-year to -$84.7 million; the TTM value through Dec 2025 reached $339.4 million, up 11135.11%, while the annual FY2025 figure was $339.4 million, 11095.79% up from the prior year.
  • Net Income towards Common Stockholders reached -$84.7 million in Q4 2025 per TGTX's latest filing, down from $390.9 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at $390.9 million in Q3 2025 and bottomed at -$94.0 million in Q4 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$2.9 million, with a median of -$25.1 million recorded in 2022.
  • The widest YoY moves for Net Income towards Common Stockholders: up 9974.61% in 2025, down 2607.86% in 2025.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$94.0 million in 2021, then surged by 196.69% to $90.9 million in 2022, then tumbled by 114.85% to -$13.5 million in 2023, then soared by 76.84% to -$3.1 million in 2024, then plummeted by 2607.86% to -$84.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Net Income towards Common Stockholders were -$84.7 million in Q4 2025, $390.9 million in Q3 2025, and $28.2 million in Q2 2025.